-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2023-509332-26-00
4
2023-02-16
Lupus Nephritis Class III-IV, +/- V
-
2023-506239-14-00
5
2022-12-13
Crohn’s Disease
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2023-507041-28-00
4
2022-11-28
Solid and Hematological Malignancies
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-500408-22-00
5
2022-09-14
Plaque Psoriasis
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-508879-36-00
5
2022-04-28
Pruritus
-
2023-509283-14-00
1
2022-04-25
Advanced non-small cell lung cancer
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2022-502519-13-00
5
2021-05-07
Moderate to Severe Plaque Psoriasis
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514962-38-00
1
2020-08-25
Solid Tumors
-
2024-515114-41-00
7
2020-08-10
Solid tumors
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease